May 24, 2013     Japanese 
  JCN 
	  Network - Home
JCN Newswire
  Home  |  Companies  | Annual Reports  |  CSR  | News Alerts     
 
Share:
ViroMed Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis
 

Tokyo, Jan 11, 2007 (JCN) - Takara Bio affiliate ViroMed Co., Ltd., based in Korea, announced the Korea Food & Drug Administration approval of their clinical trial of VM106, gene therapy treatment drug, for chronic granulomatosis.

Takara Bio's RetroNectin method was used under license in the clinical trial.

For the Retro Nectin treatment, VM106 utilizes a retro virus vector to inject gp91, the normal treatment gene, into the extracted haematopoietic stem cell of the patient. Afterwards a sample of this is injected back into the patient.

By Aki Tsukioka Contributor

Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.


 Company Profile |   Print  |   Alerts
ACN Newswire

 Recent  Takara Bio  News  
  Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial  (Jan 7, 2013)
  Takara Bio Submits IND Application for HIV-1 Gene Therapy to the FDA  (Mar 23, 2012)
  Takara Bio and Tianjin Medical University in Gene Therapy Project  (Aug 3, 2011)
  Takara Bio RetroNectin to UCLA for TCR-gene Therapy Clinical Trials in Advanced Melanoma  (Dec 18, 2008)
  Takara Bio Announces Start of Clinical Research of Cancer Immunotherapy using RetroNectin(R) Expansion Culture System at Tianjin Cancer Institute & Hospital, China  (May 2, 2008)
  Takara Bio Grants Transgenomic License for LA-PCR Technology  (May 7, 2007)
  ViroMed Obtains Clinical Trial Approval of Gene Therapy Treatment for Chronic Granulomatosis  (Jan 11, 2007)
  Takara Bio's RetroNect Used in Australia for Gene Therapy Clinical Trials of Multiple Myeloma  (Dec 18, 2006)
  Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia  (Sept 7, 2006)
  Takara Bio Offers Drug for Treatment of Chronic Lymphatic Leukemia  (Sept 7, 2006)



 Recent  Biotech News   
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)

More Biotech news...

 Recent  Biotech News   
Otsuka Launches First Skin Patch Treatment for Parkinson's Disease and Restless Legs Syndrome (Feb 22, 2013)
Teijin Launches Polyester Curtain Fabric with Enhanced Pollen-trapping (Feb 21, 2013)
Toyota Tsusho Opens Medical Clinic in Thai Plant (Feb 18, 2013)
Daiichi Sankyo Develops Nucleic Acid Treatment for Duchenne Muscular Dystrophy (Feb 15, 2013)
Dainippon Sumitomo Pharma Opens Subsidiary in Singapore (Jan 22, 2013)
Teijin and InCube Labs Enter Strategic Partnership in Healthcare Business (Jan 22, 2013)
Chugai Grants Debiopharm Group Exclusive Worldwide License for Anti-cancer Agent (Jan 9, 2013)
Takara Bio Initiates Phase 1 HIV Gene Therapy Clinical Trial (Jan 7, 2013)
Kobe University, KNC Labs and Dainippon Sumitomo to Research Anti-cancer Agent (Dec 28, 2012)
Daiichi Sankyo Introduces Alzheimer's Disease Awareness Campaign (Dec 20, 2012)

More Biotech news...
 
CSR Report Download
Annual Reports

  More >>    
Most Popular


About JCN | Privacy Policy | Terms of Use | JCN Network (日本語)